22 citations
,
April 2000 in “International Journal of Dermatology” This case report describes a 78-year-old farmer with idiopathic pulmonary fibrosis who developed cutaneous Alternaria alternata infections, which improved with reduced prednisolone and itraconazole treatment, with no recurrence after two years.
1 citations
,
November 2020 in “Asian Journal of Pharmaceutical and Clinical Research” This review discusses the potential of nanotechnology in treating idiopathic pulmonary fibrosis by targeting abnormal alveolar epithelial cells and reports no new clinical results.
82 citations
,
September 2020 in “Briefings in Bioinformatics” This study identified shared genes and pathways in idiopathic pulmonary fibrosis patients with COVID-19, suggesting these may increase mortality and pointing to potential drug targets for treatment.
177 citations
,
March 2018 in “International Journal of Molecular Sciences” This review discusses the role of mTOR kinase in pulmonary fibrosis and explores how mTOR inhibitors may help slow the progression of this condition, but it reports no new results.
January 2023 in “IntechOpen eBooks” This chapter reviews various synthetic methods for creating pharmacologically active diazines, particularly focusing on pyrimidines, and discusses their potential in clinical applications. It also examines novel synthetic strategies that improve the drug-like qualities and safety profiles of these compounds.